Infinium Global Research’s recent report on the “Global Epinephrine Autoinjector Market ((By Dosage (0.15 Mg Epinephrine Autoinjector, 0.3 Mg Epinephrine Autoinjector, and 0.5 Mg Epinephrine Autoinjector) By End-User (Hospital, Clinics, and Individual)) Global Industry Analysis, Trends, Market Size & Forecasts to 2028” provides a comprehensive outline of the factors responsible for the growth of the market. The Global Epinephrine Autoinjector Market was valued at over USD 2 Billion in 2022 and is expected to reach nearly USD 3.5 Billion in 2028, with a CAGR of nearly 8% during the forecast period.

To Know More Request a Sample of this Report: https://www.infiniumglobalresearch.com/reports/sample-request/41112

"We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2022-2028."

The Section on the Impact of COVID-19 on this Market is Included in the Report for Free

The market has grown because of a rise in the number of patients allergic to dust, insect bites and venom, food, and food additives. The actual fact that these auto-injectors are a necessary treatment for treating anaphylaxis and permit non-medical persons to effectively treat the disease will likely drive the worldwide marketplace for Epinephrine Autoinjector within the upcoming forecast period. Epinephrine is often utilized to treat life-threatening allergic responses, restore rhythm, and manage asthma. This is often an important element driving demand for epinephrine auto-injectors and is projected to contribute to epinephrine auto-injectors market adoption trends within the forecast period. A rise in new product approvals and new product launches by key players within the market is additionally expected to drive the epinephrine auto-injector market during the forecast period

The outbreak of the COVID-19 pandemic the market had mixed effects on the market during the forecast period. As the restrictions were imposed, it declined the treatment of patients with delaying seeking care and treatment in healthcare sectors. Moreover, the slowdown in run recruitment has delayed the introduction of latest therapies. These factors had a negative impact on the autoinjectors market, particularly with their use in healthcare foundations. However, the COVID-19 pandemic was accelerating the trend of self-injection, empowering patients to possess more involvement and control over their treatment.

The 0.3 Mg Epinephrine Autoinjector Segment is Expected to Dominate the Market

The Global Epinephrine Autoinjector Market is bifurcated By Dosage and End-User. By Dosage, the segment is further bifurcated into 0.15 Mg Epinephrine Autoinjector, 0.3 Mg Epinephrine Autoinjector, and 0.5 Mg Epinephrine Autoinjector. By Dosage, the 0.3 Mg Epinephrine Autoinjector segment dominated the market during the forecast period. Because of its many applications across all age groups and moderate doses, among others, 0.3mg accounted for the largest market share. The increasing utilization of the Autoinjector for the treatment of severe allergic patients enhanced the expansion of the segment during the forecast period. Epinephrine is usually recommended as a first-line therapy option by the National Institute of Allergy and Infectious Diseases. Food allergies are extremely common among children.

Enquire Here Get Customization & Check Discount for Report @ https://www.infiniumglobalresearch.com/reports/customization/41112

The North America Region is Expected to Dominate the Growth of the Global Epinephrine Autoinjector Market

The Global Epinephrine Autoinjector Market is segmented into the Asia Pacific, North America, Europe, the Middle East & Africa, and South America. The North American region to dominate the growth of the global market during the forecast period. An increase in the number of people with various types of allergies, and a high rate of adoption of generic epinephrine auto-injectors augmented the market growth in the region. Furthermore, the availability of low-cost generic epinephrine auto-injectors, in the U.S. is projected to enhance the epinephrine auto-injector market within the North American region during the forecast period. According to a study published in the JAMA Network 2019, about 10.8%, i.e. more than 26 million adults in the U.S., are food allergic; however, approximately 19% of adults believe that they have a food allergy. These factors influence the market growth in the North American region.

Key Players Focus to Increase the Production Capacity by Collaborating with other Companies

The Global Epinephrine Autoinjector Market is intensely competitive with several multinational and local players. The major players are Pfizer Inc., Mylan Inc., ALK Abello, Sanofi SA, Lincoln Medical Ltd, Teva Pharmaceuticals Ltd, Antares Pharma Inc., Hospira Inc., Impax Laboratories, Inc., Bausch & Lomb Incorporated, and several others are constantly focusing on developing products to gain a competitive edge in the market.

For instance, In August 2020, Antares Pharma (US) signed an agreement with Lunatus Global Medical Supplies (Dubai). Furthermore, SHL Medical Switzerland-based Company acquired Weibel CDS Switzerland-based Company In March 2020. Infinium Global Research’s recent report on the Global Epinephrine Autoinjector Market is an encompassment of such recent developments in the marketplace. The report delivers insights into the recent developments by leading players that have contributed to the growth of the Global Epinephrine Autoinjector Market and also estimates the impact of recent developments in the market.

Place a Purchase Order to Buy a Complete Copy of this Report Enquire Here: https://www.infiniumglobalresearch.com/reports/enquiry/41112

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of the Epinephrine Autoinjector.

=> Complete coverage of all the product types and applications segments to analyze the trends, developments, and forecast of market size up to 2028.

=> Comprehensive analysis of the companies operating in this market. The company profile includes an analysis of the product portfolio, revenue, SWOT analysis, and the latest developments of the company.

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus on to invest, consolidate, expand and/or diversify.